Evidence map›Paper›PMID 33310636›Full record

SynthesisThe International journal on drug policy2021

Reporting of substance use treatment quality in United States adult drug courts.

Paul J Joudrey, Benjamin A Howell, Kate Nyhan, Ali Moravej, Molly Doernberg, Joseph S Ross, Emily A Wang

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in The International journal on drug policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Paul J JoudreySection of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States. Electronic address: paul.joudrey@yale.edu.
Benjamin A HowellSection of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; VA Connecticut Healthcare System, West Haven, CT. United States; National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; SEICHE Center, Yale School of Medicine, New Haven, CT,  United States.
Kate NyhanCenter for Biomedical Data Science, Cushing/Whitney Medical Library, Yale School of Medicine.
Ali MoravejYale School of Public Health, New Haven, CT, United States.
Molly DoernbergYale School of Public Health, New Haven, CT, United States.
Joseph S RossSection of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, United States; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, United States.
Emily A WangSection of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; SEICHE Center, Yale School of Medicine, New Haven, CT,  United States.
Yale University · USVA Connecticut Healthcare System · USWhitney Museum of American Art · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale-Mayo FDA Center for Excellence in Regulatory Science and InnovationU01FD005938 · FDA · YALE UNIVERSITY · PI Joseph Solomon Ross · 2016 to 2026
$25.4M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
Yale Drug use, Addiction and HIV Research Scholars (DAHRS)K12DA033312 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Patrick O'Connor · 2013 to 2026
$7.2M
Understanding hospital value: provider, hospital and community effectsR01HS022882 · AHRQ · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HORWITZ, LEORA · 2014 to 2023
$2.9M
Leveraging Physician Networks to Improve Care and Outcomes for Low-Income PopulationsR01HL144644 · NHLBI · YALE UNIVERSITY · PI NDUMELE, CHIMA · 2019 to 2021
$1.6M
Medical reversals: De-implementing ineffective and unsafe treatmentsR01HS025164 · AHRQ · UNIVERSITY OF MINNESOTA · PI KARACA-MANDIC, PINAR · 2017 to 2020
$1.4M
Optimizing Medical Device Post-Market Surveillance for Public ValueU01FD004585 · FDA · YALE UNIVERSITY · PI KRUMHOLZ, HARLAN MARC · 2012 to 2016
$592k
AHRQ HHS R01 HS022882AHRQ HHS R01 HS025164FDA HHS U01 FD004585FDA HHS U01 FD005938NCATS NIH HHS TL1 TR001864NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL144644NIDA NIH HHS K12 DA033312NIDA NIH HHS L30 DA052056
6 · The paper itself

Abstract

backgroundAdult drug courts are growing in popularity within the Unites States, but the quality of substance use treatment within drug court programs and the impact of drug courts on health and substance use treatment outcomes is largely unknown. We appraised the quality of United States adult drug court process evaluations and the inclusion of measures of substance use treatment quality.

methodsWe systematically reviewed the adult drug court evaluations between 2008 and 2018 in accordance with recommended strategies for systematic gray literature search. We appraised evaluation quality using the Evidence for Policy and Practice Information and Coordination Center tool for process evaluations. We extracted recommended measures of substance use treatment quality, including measures related to screening and monitoring, diagnosis, service availability, service utilization, and outcomes.

resultsOur search identified 112 evaluations. Process measures were included within 68 evaluations, 45% of which had poor data reliability. We found that less than 10% of evaluations reported substance use treatment quality measures related to service utilization, overdose, and mortality, while more than 75% contained criminal justice measures, including program graduation (completion of criminal justice proceedings) and participant recidivism.

conclusionsWe found low uptake of measures of substance use treatment quality. The absence of data call into question the ability of drug courts to stem harmful substance use related health outcomes.

Indexed as

Pharmaceutical PreparationsRecidivismSubstance-Related DisordersAdultCriminal LawHumansReproducibility of ResultsUnited StatesPharmaceutical PreparationsDrug courtsEvaluationSubstance use disordersTreatment quality

Identifiers

PMID33310636
PMCPMC8046712
OpenAlexW3113168845

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.